BindingDB logo
myBDB logout

46 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26463133 22 Influence of polar side chains modifications on the dual enkephalinase inhibitory activity and conformation of human opiorphin, a pain perception related peptide.EBI Institute of Advanced Chemistry of Catalonia (IQAC-CSIC)
26241877 7 Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.EBI Pharmaleads
24927250 18 New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.EBI Pharmaleads , Paris BioPark, 11 Rue Watt, 75013 Paris, France.
24767848 2 Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor.EBI University of Siena
24735644 19 Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid- hydrolysis.EBI INSERM
18078750 76 Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.EBI GlaxoSmithKline
 20 Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetylsEBI TBA
 26 Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetylsEBI TBA
 30 Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptidesEBI TBA
21381769 56 Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.EBI Universite£ de Sherbrooke
22861813 42 Novelß-amino acid derivatives as inhibitors of cathepsin A.EBI Sanofi-Aventis Deutschland GmbH
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
22224710 44 Structure-activity relationship study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties.EBI Institute of Advanced Chemistry of Catalonia (IQAC-CSIC)
18160283 26 Targeting ACE and ECE with dual acting inhibitors.EBI Universit£ de Montr£al
16220969 219 Designed multiple ligands. An emerging drug discovery paradigm.EBI Organon Laboratories
15658862 30 Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.EBI University Institute of Pathology
12852763 20 Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.EBI Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
11585456 8 Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.EBI INSERM
9554884 72 Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.EBI Novartis Pharmaceuticals Corporation
1348542 23 Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.EBI INSERM
 29 Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11EBI TBA
 15 Synthesis and evaluation of 2-(biphenylmethyl)glutaric acid amide derivatives as neutral endopeptidase inhibitors.EBI TBA
 65 Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitorsEBI TBA
 66 Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptidesEBI TBA
21937235 7 Structure-based design of dipeptide derivatives for the human neutral endopeptidase.EBI Kao Corporation
21515054 25 Synthesis and evaluation of heteroarylalanine diacids as potent and selective neutral endopeptidase inhibitors.EBI Pfizer Inc.
19899765 69 Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.EBI CEA, DSV, Service d'Ingenierie Moleculaire des Proteines (SIMOPRO)
 25 Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by tricyclic benzazepinone thiolsEBI TBA
 8 Studies on the structural feature of S'1 subsite of neprilysin (EC.3.4.24.11): Stereochemical requirement for the enzyme-inhibitor docking processEBI TBA
 3 Non-peptidic inhibitors of neutral endopeptidase 24.11 2. Design and pharmacology of orally active phosphonate prodrugsEBI TBA
 2 Synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained gauche (−) dipeptide mimeticsEBI TBA
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18507370 7 Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2.EBI Mount Sinai School of Medicine
18243695 44 Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.EBI GlaxoSmithKline
17070062 16 Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.EBI Pfizer Global Research and Development
16821800 96 Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.EBI Pfizer Global Research and Development
11551755 18 Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI British Biotech Pharmaceuticals Limited
11384231 26 2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.EBI F. Hoffmann-La Roche Ltd.
9046341 44 Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.EBI CIBA-GEIGY Corporation
9046340 23 Ortho-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.EBI Novartis Pharmaceuticals Corporation
8360886 4 A mechanism-based inactivation study of neutral endopeptidase 24.11.EBI Salk Biotechnology/Industrial Associates
8164250 54 New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.EBI INSERM
23339426 46 In vitro inhibition effect and structure-activity relationships of some saccharin derivatives on erythrocyte carbonic anhydrase I and II.BDB Sakarya University